Leading pathology laboratories deploy tele-diagnostics with Philips during the COVID-19 pandemic
Pathology laboratories around the globe fully digitize tumor tissue samples to maintain the patient diagnostic experience while providing for staff safety
Digital transformation modernizes cancer care by enabling telehealth and the use of artificial intelligence (AI) while supporting physicians with integrated oncology informatics
Amsterdam, The Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced leading pathology laboratories across North America, Europe, and Asia have implemented full digitization for their histology samples based on the Philips Digital Pathology scanner and imaging-informatics solutions. Digital images are required to unlock the potential of digital pathology. Remote reviewing of pathological cases is essential to prevent delay in critical patient diagnosis and care, particularly during COVID-19.
During the pandemic, many pathologists, oncologists, and radiologists continued their work from home. This created an unprecedented need for home workstations and secure clinical informatics solutions allowing clinicians to read images remotely and enabling real-time virtual collaboration between their multi-disciplinary care teams. Pre-COVID-19, pathology labs that digitized their workflows across different sites reported improved collaboration and an average productivity gain of 21%.
Cancer diagnostics are becoming more and more specialized, and the workload per cancer case is increasing. Compared to the relative deficit of pathologists, it is obvious that something needs to be done to maintain a sound health service for cancer patients. Digitization is part of the solution. Digital pathology gives us a better utilization of expertise and recourses, both regional and national. It also enables us to take advantage of digital analysis and AI.
Head of the Department of Pathology, St. Olavs Hospital
“COVID-19 has become a catalyst for change – a defining moment for all of us to reimagine healthcare the way it should be”With a focus on the people at the center of cancer care, we work to innovate workflows, remove barriers of fragmented systems, and bring insights directly to care providers to support excellent cancer care.”
Chief Business Leader, Precision Diagnosis at Philips
Shared decision-making, pathway selection and treatment
Philips’ solutions for oncology and digital pathology can help transform and enhance the multi-disciplinary workflows, including the oncology tumor board and care pathways process. Critical patient data is integrated for both oncologists, radiologists and pathologists, allowing them to collaborate efficiently, even when working remotely. The Philips platform supports streamlined preparation, enhances review and analysis, and empowers the cancer care team to reach clinical treatment decisions based on disease-specific dashboards, diagnostic images, reports, and structured patient data. Visit Philips Digital Pathology for more information on how Philips is enhancing digital pathology workflows. Visit Philips Live at RSNA 2020 to learn how Philips integrated workflow solutions connect data, technology and people across the diagnostic enterprise, helping to redefine radiology workflow efficiencies.
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
Napsauttamalla linkkiä poistut viralliselta Philips Electronics Ltd:n ("Philips") verkkosivustolta. Kaikki tällä sivustolla mahdollisesti olevat linkit kolmansien osapuolten verkkosivustoille tarjotaan vain avuksesi, eivätkä ne millään tavalla edusta minkäänlaista yhteyttä tai tukea näillä linkitetyillä verkkosivustoilla annettuihin tietoihin. Philips ei anna minkäänlaisia väitteitä tai takuita kolmansien osapuolien verkkosivustoista tai niiden sisältämistä tiedoista.